Search results
Added:
7 months ago
Source:
Radcliffe Cardiology
The ODYSSEY-HCM trial, evaluating the cardiac myosin inhibitor mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM), did not meet its dual primary endpoints for improving functional capacity or patient-reported symptoms.¹ The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England…
View more
Pistas Clínicas en Enfermedades Cardiovasculares
Video Series
Indizi Clinici nelle Malattie Cardiovascolari
Video Series
Demetri Yannopoulos
Research Area(s) / Expertise:
Job title: Professor of Medicine
Author
Steven E Nissen
Research Area(s) / Expertise:
Job title: Cardiologist
Author
Martin B Leon
Research Area(s) / Expertise:
Job title: Professor of Medicine
Author
Marcelo F Di Carli
Research Area(s) / Expertise:
Job title: Director, CV Imaging
Author
Andrew JS Coats
Research Area(s) / Expertise:
Job title: Professor of Cardiology and Scientific Director
Author
Vivek Reddy
Research Area(s) / Expertise:
Job title: Director of Cardiac Arrhythmia Services
Author
Added:
4 months ago
Source:
Radcliffe Cardiology
A new post hoc analysis of the SUMMIT trial suggests the HFpEF-ABA score is a more effective and inclusive enrichment tool than natriuretic peptide (NP) levels for clinical trials in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).¹ The findings indicate the score, which is based on age, body mass index (BMI), and history of atrial fibrillation (AF), can…
View more